MX339907B - Bifidobacterium longum. - Google Patents

Bifidobacterium longum.

Info

Publication number
MX339907B
MX339907B MX2011005006A MX2011005006A MX339907B MX 339907 B MX339907 B MX 339907B MX 2011005006 A MX2011005006 A MX 2011005006A MX 2011005006 A MX2011005006 A MX 2011005006A MX 339907 B MX339907 B MX 339907B
Authority
MX
Mexico
Prior art keywords
bifidobacterium longum
genome
multiple embodiments
various novel
embodiments described
Prior art date
Application number
MX2011005006A
Other languages
English (en)
Other versions
MX2011005006A (es
Inventor
O'mahony Liam
Larry Charbonneau Duane
Van Sinderen Douwe
Xu Jun
Steven Zhao Wenzhu
a grant Raymond
Song Yuli
Bascom Charles
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of MX2011005006A publication Critical patent/MX2011005006A/es
Publication of MX339907B publication Critical patent/MX339907B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/061—Addition of, or treatment with, microorganisms
    • A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A23L2/382—Other non-alcoholic beverages fermented
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a las múltiples modalidades descritas en la presente comprenden el genoma de una cepa de probiótico Bifidobacterium Iongum y los genes codificados por el genoma. Se describen diversas variedades de Bifidobacterium Iongum nuevas. Una cepa aislada de Bifidobacterium longum BL1207 (PTA.9608). Una formulación que comprende una cepa aislada de Bifidobacterium longum. El uso de una cepa de Bifidobacterium Iongum como cepa probiótica.
MX2011005006A 2008-11-11 2009-11-11 Bifidobacterium longum. MX339907B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11351308P 2008-11-11 2008-11-11
US14998009P 2009-02-04 2009-02-04
PCT/IE2009/000079 WO2010055499A2 (en) 2008-11-11 2009-11-11 Bifidobacterium longum

Publications (2)

Publication Number Publication Date
MX2011005006A MX2011005006A (es) 2011-05-24
MX339907B true MX339907B (es) 2016-06-14

Family

ID=41572466

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2016005356A MX349706B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.
MX2011005006A MX339907B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.
MX2016005357A MX349705B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.
MX2016005358A MX356598B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016005356A MX349706B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016005357A MX349705B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.
MX2016005358A MX356598B (es) 2008-11-11 2009-11-11 Bifidobacterium longum.

Country Status (11)

Country Link
US (3) US9771624B2 (es)
EP (1) EP2352389B1 (es)
CN (1) CN102984955B (es)
AU (1) AU2009315298A1 (es)
BR (1) BRPI0921758A2 (es)
CA (3) CA2852479C (es)
ES (1) ES2566496T3 (es)
MX (4) MX349706B (es)
PL (1) PL2352389T3 (es)
RU (1) RU2570557C2 (es)
WO (1) WO2010055499A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709398B2 (en) * 2007-03-28 2014-04-29 Alimentary Health Limited Probiotic Bifidobacterium strains
ES2566496T3 (es) 2008-11-11 2016-04-13 Alimentary Health Limited Bifidobacterium longum
EP2283810A1 (en) * 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
PL2823822T3 (pl) * 2009-11-11 2017-09-29 Alimentary Health Limited Szczep Bifidobakterium
AU2010317422A1 (en) * 2009-11-11 2012-05-31 Alimentary Health Limited Probiotic Bifidobacterium strain
US9259019B2 (en) 2010-11-11 2016-02-16 Mars, Incorporated Bifidobacteriumstrain
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
CN108771687A (zh) 2012-02-29 2018-11-09 伊西康内外科公司 微生物区系的组合物及与其相关的方法
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
KR102271292B1 (ko) 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
WO2015074054A1 (en) * 2013-11-18 2015-05-21 The Trustees Of Columbia University In The City Of New York Improving microbial fitness in the mammalian gut
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
MX2017005260A (es) 2014-10-24 2018-01-30 Evolve Biosystems Inc Bifidobacterias activadas y metodos de uso de las mismas.
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US9913800B2 (en) 2015-04-28 2018-03-13 The Procter & Gamble Company Compositions and methods for improving skin health
CN104894005B (zh) * 2015-04-30 2018-05-22 江苏紫石微康生物科技有限公司 一种高产胞外多糖的乳酸菌bl21及制备方法和应用
RU2614116C2 (ru) * 2015-07-21 2017-03-22 Головин Михаил Анатольевич Способ получения пробиотической композиции
WO2017035426A1 (en) 2015-08-27 2017-03-02 The Procter & Gamble Company Bifidobacterium longum
US20180280453A1 (en) * 2015-08-27 2018-10-04 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN109069552B (zh) * 2015-12-11 2023-01-24 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的长双歧杆菌
CN105907682A (zh) * 2016-05-31 2016-08-31 深圳先进技术研究院 一种产高粘性多糖的细菌的筛选方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
US11771723B2 (en) 2018-01-29 2023-10-03 Precisionbiotics Group Limited Bifidobacterium longum NCIMB 41676
KR20200128672A (ko) 2018-01-29 2020-11-16 프리시젼바이오틱스 그룹 리미티드 비피도박테리움 롱검 ncimb 41676
WO2019145570A1 (en) 2018-01-29 2019-08-01 Alimentary Health Limited A combination product for prophylaxis and treatment of irritable bowel syndrome
US20200289588A1 (en) * 2018-01-29 2020-09-17 Precisionbiotics Group Limited Bifidobacterium longum ncimb 41676
EP3745871A1 (en) * 2018-01-29 2020-12-09 PrecisionBiotics Group Limited Bifidobacterium longum ncimb 41676
US11752178B2 (en) 2019-04-17 2023-09-12 Nutech Ventures Methods for the isolation of microbes with enhanced persistance and compositions with such microbes
CN110205393B (zh) * 2019-07-03 2020-07-24 南京先声医学检验有限公司 用于检测营养代谢能力相关snp位点的引物组、应用、产品及方法
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
WO2021077543A1 (zh) * 2019-10-23 2021-04-29 江南大学 一种亚油酸异构酶及其在共轭亚油酸生产中的应用
CN112391484B (zh) * 2020-11-17 2022-12-27 江南大学 一种定量检测长双歧杆菌菌株的方法
WO2023137381A2 (en) * 2022-01-12 2023-07-20 Washington University Bifidobacterium infantis formulations
CN114507649B (zh) * 2022-02-16 2023-11-21 吉林大学 嗜热酶及一锅法高效合成udp-葡萄糖和udp-葡萄糖醛酸的方法
CN114774335B (zh) * 2022-06-22 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 具有靶向葡萄糖激酶显著降血糖和降血脂功效的长双歧杆菌070103及其应用
CN117568301B (zh) * 2023-11-16 2024-05-10 安徽农业大学 一种通过糖多孢红霉菌sace_1646基因提高红霉素产量的方法
CN118086539A (zh) * 2024-03-05 2024-05-28 中国食品发酵工业研究院有限公司 长双歧杆菌婴儿亚种的PMA-qPCR活菌定量检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049115A1 (en) 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
ATE551063T1 (de) * 2006-02-15 2012-04-15 Nestec Sa Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
RU2333655C2 (ru) * 2006-07-26 2008-09-20 Государственное образовательное учреждение высшего профессионального образования Восточно-Сибирский государственный технологический университет Способ получения селенсодержащей биологически активной добавки
EP2318513B1 (en) 2008-07-11 2012-09-19 Chr. Hansen A/S New probiotic bifidobacterium longum
ES2566496T3 (es) 2008-11-11 2016-04-13 Alimentary Health Limited Bifidobacterium longum

Also Published As

Publication number Publication date
CA2852479C (en) 2017-01-24
MX356598B (es) 2018-06-04
BRPI0921758A2 (pt) 2019-07-30
RU2570557C2 (ru) 2015-12-10
EP2352389B1 (en) 2016-01-06
MX349705B (es) 2017-08-09
US10689719B2 (en) 2020-06-23
PL2352389T3 (pl) 2016-07-29
CA2741942A1 (en) 2010-05-20
MX349706B (es) 2017-08-09
CN102984955A (zh) 2013-03-20
CA2852487C (en) 2017-01-31
MX2011005006A (es) 2011-05-24
WO2010055499A3 (en) 2010-09-23
EP2352389A2 (en) 2011-08-10
US20200377961A1 (en) 2020-12-03
ES2566496T3 (es) 2016-04-13
US9771624B2 (en) 2017-09-26
WO2010055499A2 (en) 2010-05-20
CN102984955B (zh) 2015-01-07
CA2852487A1 (en) 2010-05-20
RU2011120271A (ru) 2012-12-20
CA2741942C (en) 2018-01-16
US20100183559A1 (en) 2010-07-22
AU2009315298A1 (en) 2010-05-20
US20180016647A1 (en) 2018-01-18
CA2852479A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
MX356598B (es) Bifidobacterium longum.
PL2134833T3 (pl) Probiotyczny szczep Bifidobacterium
GB2460781B (en) Probiotic bifidobacterium strains
HK1152968A1 (en) New probiotic bifidobacterium longum
MX2012005524A (es) Cepa de probioticos bifidobacterium.
MY156849A (en) Novel lactobacillus plantarum and composition comprising the same
WO2009120762A3 (en) Human cardiovascular progenitor cells
WO2009122042A3 (fr) Souche de lactobacillus rhamnosus
NZ601532A (en) Method for constructing novel bacterium belonging to the genus bifidobacterium
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
IL289610A (en) Bacterial strain Bifidobacterium bifidum, its preparations and related uses
MY158310A (en) Prevention and treatment of allergic diarrhoea
WO2008002484A3 (en) Novel lactobacillus bulgaricus strain and compositions
PL380803A1 (pl) Nowy szczep Bifidobacterium longum
RU2010121552A (ru) Штамм bifidobacterium longum гв-9, используемый для получения бифидосодержащей продукции
GEU20111671Y (en) Probiotic preparation having capsule form
RU2010119250A (ru) Штамм bifidobacterium adolescentis рвв-1, используемый для получения продукции
UA29662U (ru) Штамм lactobacillus plantarum 7-317 для изготовления пробиотиков для птиц
RU2010121553A (ru) Штамм bifidobacterium bifidum 74-23, используемый для получения бифидосодержащей продукции
AU2006905424A0 (en) Probiotic lactobacillus strains
MX2010007695A (es) Medios resistentes a abrasion.
RU2010119242A (ru) Штамм bifidobacterium longum го-10, используемый для получения бифидосодержащей продукции
RU2010119240A (ru) Штамм bifidobacterium bifidum 79-97, используемый для получения бифидосодержащей продукции
PL380804A1 (pl) Nowy szczep Lactobacillus rhamnosus
PL382760A1 (pl) Nowy szczep bakterii mlekowych Lactobacillus casei

Legal Events

Date Code Title Description
FG Grant or registration